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There continues to be a need for innovative and inexpen-
sive drugs to treat diseases of the developing world.
1,2 It is
also important to link academic training and research to
critical societal needs. Indiana University-Purdue University
Indianapolis (IUPUI) is addressing both these concerns by
developing a concept called “Distributed Drug Discovery”
(D
3).
3 This Perspective describes how D
3 can harness
combinatorial chemistry, distributed over multiple academic
and industrial locations, to educate students while they
perform a key role in the early stages of drug lead discovery
for developing world and otherwise neglected diseases. Two
other articles in this issue of the Journal of Combinatorial
Chemistry present case histories implementing the chemistry
component of D
3. One involves replicated D
3 syntheses in
the United States, Poland, Russia, and Spain.
4 The second
is an application in which students at IUPUI make analogs
of a potential anticancer agent.
5 In this Perspective, D
3 is
discussed in three parts: (I) The Concept of D
3, (II) The Role
of Combinatorial Chemistry in D
3, and (III) Implementation
of D
3.
Part I. The Concept of D
3
It is difﬁcult to ﬁnd resources to discover drugs to treat
diseases in the developing world.
1,2 In the developed world,
economic incentives have fueled drug discovery, ﬁnancing
the expensive equipment, procedures, and personnel currently
required by the pharmaceutical industry. Unfortunately, the
burden of disease is disproportionately focused in poor
nations, and there is not the same economic incentive for
the pharmaceutical industry to discover drugs for diseases
of the developing world.
6
Distributed Drug Discovery (D
3) proposes that if simple,
inexpensive equipment and procedures are developed for
research in each of the core drug-lead discovery stages,
computational chemistry, synthetic chemistry, and biochemi-
cal screening, this large research challenge can be divided
into manageable smaller units and carried out, in parallel, at
multiple academic and industrial sites. The academic sites
will be located in both the developed and developing world.
The industrial locations can be stand-alone nonproﬁts,
private-public partnerships, or nonproﬁt initiatives within
corporations.
7 The coordinated and recombined results of
these distributed resources can economically accelerate the
identiﬁcation of leads in the early stages of the drug discovery
process. Simultaneously, this effort provides educational and
job opportunities in both the developed and developing
worlds, while building cultural and economic bridges for the
common good. This distribution of problem solving at the
three core stages of drug-lead discovery is shown schemati-
cally in Figure 1.
Stage One D
3: Distributed Computational Analysis.
Independent of the integrated D
3 process proposed here,
scientists have demonstrated the viability and power of a
distributed problem solving approach at the computational
stage of drug discovery.
8 The Web site Grid.org
9a describes
how a screen saver surrogate process permits computational
screening of a virtual library of over 35 million potential
drug molecules, to identify those that might interact with
protein targets relevant to the treatment of smallpox. A
similar distributed project has been organized by the World
Community Grid, with malaria as one of the targeted
diseases.
9b The Schools Malaria Project is an excellent
example of how distributed computation and education can
be combined to address a developing world disease
challenge.
8h These sites (and the pioneering “SETI” project
9c)
demonstrate the power of dividing a large computational
problem into smaller units and distributing them to individual
PCs that have the required problem-solving software. In these
distributed computational examples, free programs that run
on idle PCs are powerfully combined to process large data
sets and economically solve resource-intensive computational
problems.
Stage Two D
3: Distributed Chemical Synthesis. We
believe an analogous process can be developed and employed
at the synthesis stage of drug-lead discovery. The distributed
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graduate and graduate academic laboratories, as they receive
education and do research in organic synthesis. Temporarily
idle resources at private, public, and other nonproﬁt synthetic
laboratories around the world will serve as additional
distributed synthetic sites.
By utilizing combinatorial chemistry and the equipment
discussed in Part II of this Perspective, D
3 will capitalize
on a tight integration of Stage One computational analysis
with realistic Stage Two synthetic capability. Well-prece-
dented virtual D
3 catalogs (discussed in detail in Part II) are
key to this integration. Their precedented nature gives
assurance that potential drug-lead molecules, computationally
selected from these virtual catalogs, will be synthetically
accessible by students and researchers utilizing simple, low-
cost, globally distributed equipment and procedures.
Stage Three D
3: Distributed Biological Screening. All
the products from these synthetic efforts can be tested by
distributed biological screening, if developed in an analogous
fashion and integrated into educational, private, public, or
other nonproﬁt laboratories. Although we are not aware of
current examples of a distributed screening process, we
believe that the D
3 concept, coupled with the documented
examples of distributed problem solving in Stage One
computation and Stage Two synthesis, will provide incentive
for our biological colleagues to develop their own distributed
methodology for Stage Three screening. Meanwhile, high-
throughput screening resources are available through the NIH
Molecular Libraries Initiative.
10
Integrating All the Stages of D
3: The Role of Informa-
tion Technology. D
3 will utilize appropriate information
technology, open-access-based when available,
11,12 to enable
and coordinate the critical elements of all three core
disciplines:
(1) Stage One enumeration and computational analysis of
virtual D
3 catalogs for the identiﬁcation of potential
developing world disease drug-leads. The resulting
targeted molecules will be tabulated in a format readily
accessible and understandable to chemists.
(2) Facilitation and tracking, at Stage Two, of the
distribution and synthetic fate of these selected
molecules. Which ones have institutions chosen to
make? What are their results? Is their quality accept-
able? Are they available for screening? How do
biologists obtain them?
(3) Tracking, at Stage Three, of the distribution and
screening of the synthesized molecules.
Partnering with the NIH Molecular Library Initiative may
provide solutions to many of these shared informatics
needs.
10
The Power and Potential of Distributed Drug Discov-
ery. There has been considerable discussion regarding the
beneﬁts and drawbacks of a proﬁt-driven drug discovery
process.
6,13 On the one hand, the proﬁt motive has provided
incentives for the pharmaceutical industry to invest in the
human and material resources that have revolutionized the
treatment of diabetes, hypertension, cancer, AIDS and other
debilitating or deadly diseases. The pharmaceutical industry
can be justiﬁably proud of its role in these life-changing drug
discoveries. On the other hand, research requiring a proﬁt
results in neglected diseases when patients cannot afford to
pay for the drug discovery costs. In addition, because of
intellectual property concerns, this proﬁt dependence has
restricted the sharing of information and resources that could
otherwise facilitate drug discovery.
Distributed Drug Discovery addresses these limitations.
Its vision is pragmatic and compelling: by developing and
utilizing economical equipment and straightforward proce-
dures, large research problems can be broken down into
manageable smaller units to be solved by individual scientists
at multiple sites throughout the developing and developed
world. Students will have the tools to be educated and do
research in important health-related scientiﬁc disciplines.
While education is taking place, they will simultaneously
make and test chemical candidates for drug-lead discovery.
This coupling of training and research enables students to
clearly understand the value and purpose of their education.
By incorporating the initial stages of the drug discovery
process into college and university education, costs are
minimized while at the same time scientists of the future
are trained. With little proﬁt incentive, sharing discovery
through the D
3 process becomes an asset, not a liability. With
the removal of barriers to the global sharing of information
and resources, Distributed Drug Discovery provides access
to untapped intellectual and practical potential.
11,13 Patents
will only be pursued in those situations where they facilitate,
Figure 1. Diagram of distributed problem solving at three stages of Distributed Drug Discovery.
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low cost drugs to those in need.
13h
When spread over global sites, D
3 becomes a potent drug-
lead discovery process, forging a closer geographical and
cultural connection between those in need and those trying
to meet those needs. To rephrase a classical saying: “Give
people medicine and they will depend on you for their health;
teach people to discover medicines and they will develop
cures themselves.”
14 It is our hope that D
3 will enable the
lead discovery phase of this goal, and that other organizations
will develop these leads to the ﬁnal drug stage.
2,6,7,11
Part II. The Role of Combinatorial Chemistry in
Distributed Drug Discovery
A major focus of this Perspective is to describe the role
combinatorial chemistry can perform in enabling distributed
synthesis at Stage Two of D
3. For successful implementation
at this stage there must be well-documented virtual D
3
catalogs and cost-effective, reproducible synthetic procedures
to make the large number of potential drug-lead molecules
selected from them. Clearly combinatorial chemistry is a
prime candidate to fulﬁll this need. The chemical economy
and effectiveness of a combinatorial discovery process cannot
be disputed. In nature a set of only 24 starting materials (4
nucleotides and 20 amino acids) is sufﬁcient to provide,
through combinatorial chemistry, the materials and synthesis
instructions to create all the proteins essential for the
functioning and protection of life. This includes the huge
combinatorial library of unique antibody molecules coded
for and expressed by the body’s B-cell repertoire.
15 They
are a key component of our endogenous drug discovery
factory, the immune system. In a few days’ time, antibodies
are selected from this library and scaled up for production,
to ﬁght infections and other assaults on the body by foreign
substances.
Chemists have attempted to learn from nature’s powerful
combinatorial examples and implement an analogous process
in an organic chemistry laboratory setting. Solutions to some
key challenges shared by the combinatorial chemistry
discipline and D
3 are discussed in the following sections.
16
Rationally Selecting Candidate Molecules: The Role
of Virtual D
3 Catalogs. Computational analysis is now
commonly used to select or design potential drug leads prior
to synthesis. However, often this process does not consider
if the selected molecules can be made by any simple, known
procedure. On the other hand, combinatorial chemistry can
enable the synthesis of many molecules, but sometimes
without regard for theoretical activity. Researchers who are
expert in both of these areas can help narrow this com-
munication gap. In general, however, computational special-
ists cannot be expected to be experts at synthesis, nor can
the synthetic chemists be experts in computational analysis.
An effective way of bridging this divide is to provide
computational chemists with comprehensive information that
captures and translates for them the knowledge and capability
of the synthetic chemist. Currently, one of the most direct
ways of accomplishing this goal is to encode, for the
computational chemists, synthetic expertise in the form of
virtual libraries (or, as we refer to them in D
3, virtual
“catalogs”):
17 collections of theoretical molecules accessible
by known chemistry. Virtual libraries can readily be con-
structed with available enumeration packages based on
known synthetic transformations operating on available
reagents.
18 They are especially valuable when the classes of
molecules constructed are “biased”, that is, they resemble
structures with known or expected biological activity. When
these virtual libraries have been enumerated using reagents
with predictable reactivity and synthetic routes that are well
documented, the computational chemist, with no knowledge
of synthesis, can use virtual screening tools to conﬁdently
select target molecules that can realistically be prepared.
19
Unfortunately, the utility of virtual libraries often suffers
from major limitations: (1) They may not be representative
of classes of molecules with promising biological activity.
(2) Because of intellectual property concerns and technical
issues, such libraries are not universally available for
comprehensive computational analyses. (3) Depending on
documentation and precedent, the successful synthesis of any
selected “virtual” molecule can be wildly unpredictable. This
is where D
3 comes into play. As depicted in Figure 2, the
following steps integrate computational analysis and realistic
D
3 synthesis:
(1) Combinatorial chemistry based on straightforward
methodologies and inexpensive equipment is devel-
oped to enable the synthesis of promising structural
types. All the reagents compatible with this chemistry
are identiﬁed from commercial or other sources
(Figure 2A).
(2) With D
3 equipment and procedures, many of these
potential reagents are tested at the appropriate step in
the combinatorial synthesis (Figure 2A and B). This
rehearsal
20 can be an integral part of the educational
process, with replicated evaluation at globally distrib-
uted educational laboratories.
4
Figure 2. Role of D
3-based virtual catalogs in integrating computational analysis with synthesis.
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3 catalogs are enumerated
18 from these and
other validated reagents (Figure 2B and C). We have
chosen to term these collections of molecules virtual
“catalogs” rather than “libraries” to distinguish them
from enumerated libraries based on more hypothetical
or complicated chemistry or on unvalidated reagents
and procedures. The term “catalog” emphasizes the
greater likelihood of synthetic accessibility for mol-
ecules contained within a virtual D
3 library. These
catalogs are made freely available globally for analysis
by the entire scientiﬁc community.
(4) Distributed computational analysis is performed on
these large virtual catalogs (possibly >10
6 com-
pounds), against models appropriate for developing
world or neglected disease targets.
8 This yields a
smaller list of potential drug lead candidates (Figure
2C and D) which are accessible by D
3 syntheses.
(5) This list of proposed drug leads (D) is subdivided into
smaller sets, which can be chosen by different
laboratories for replicated distributed synthesis (Figure
2D and E). For example, a list of 1000 compounds
step D could be divided into 50 sets of 20 compounds
each. The earlier rehearsal process (A to B) will have
already conﬁrmed the viability of the required chem-
istry. The inexpensive equipment (see Part III) can
be manufactured locally and the distributed synthesis
(i.e., D to E) conducted, at 50 sites, as part of
educational programs that train students in organic
synthesis while simultaneously making potential drug
leads.
The computational component of D
3 will take full advan-
tage of open-source, web-based, internationally distributed
methodologies
8 to analyze these large, global, virtual D
3
catalogs, using computational models for developing world
disease targets.
8e Speciﬁc examples of distributed computa-
tion applied to neglected diseases are the “WISDOM”
project,
21 and Schools Malaria Project
8h which search
libraries of molecules for potential antimalaria drugs.
On the synthetic side, these virtual D
3 catalogs will be
constructed with the signiﬁcant constraint that they be
realistic virtual libraries, based on reagents whose synthetic
suitability has various levels of precedent. They will be either
completely rehearsed (i.e., that actual reagent has been
successfully employed using a D
3 protocol) or well-prece-
dented, based on a close resemblance to completely rehearsed
reagents or published work using related chemistry. By this
more comprehensive integration of computational tools with
realistic and cost-effective synthetic capability, D
3 should
greatly advance both the selection and synthesis of appropri-
ate molecular candidates. This is possible because such target
molecules will be simultaneously computationally desirable,
synthetically accessible, and resource enabled. The expertise
of the computational chemists will determine the structures
to be made. Molecules will be synthesized and tested in a
distributed fashion and the data captured and analyzed to
enable iterative computational analysis and subsequent
development work.
D
3 will establish a coordinated information network of
computational, synthetic, and biochemical screening re-
sources. To link computational expertise and synthesis goals,
we envision this network as a globally accessible resource
for both virtual D
3 catalogs and the desired disease speciﬁc
target structures derived from their computational analysis
(Figure 3). It will facilitate distributed selection, synthesis,
and screening of molecules and gathering and analyzing the
resulting information. This network will require careful
design for easy use by each scientiﬁc discipline within the
global community. To encourage participation of all the
respective scientiﬁc expertise, it should incorporate an
advocacy component for the potential of D
3. It will be an
excellent candidate for sponsorship by nonproﬁts that want
to facilitate the discovery of drugs for developing world and
otherwise neglected diseases.
2,7
Synthesizing Targeted Molecules by Reproducible
Synthetic Routes that Permit Ready and Comprehensive
Analog Synthesis and Follow-up Work. Combinatorial D
3
chemists should have conﬁdence that they can synthesize
any individual member of a virtual library. In addition, in
lead discovery, they need to be able to quickly remake,
modify, and scale-up active molecules identiﬁed through the
screening process, both for secondary screening and to
improve on their properties through analog synthesis. For
in vitro enzyme, receptor, or cell-based assays, this can
involve the synthesis (and resynthesis) of anywhere from a
few milligrams to several grams of compound. Accomplish-
ing this has sometimes been a difﬁcult or impossible task,
and negative examples are cited in arguments for avoiding
combinatorial chemistry altogether.
16 Especially problematic
has been batch to batch variability in the resynthesis of
compounds made “in house” or problems resynthesizing,
from poorly documented or unavailable protocols, com-
pounds obtained from external sources. To avoid the resulting
Figure 3. Globally accessible databases of D
3 target molecules.
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quantity scale-up, industry is increasingly preparing or
purchasing larger quantities of puriﬁed compounds.
D
3 addresses these issues by placing a strong emphasis
on reproducibility and wide synthetic capability to a degree
that we believe is unprecedented in the synthetic world. At
its core is the ability to reproducibly synthesize, in a
worldwide distributed network, large numbers of molecules.
This reproducibility challenge is met because, by virtue of
its low expense and distributed nature, all syntheses are
replicated by at least one other student-chemist, often at more
than one site and globally distant locations. This replication
process is done in both the assessment of potential D
3
reagents (reagent rehearsal) and targeted synthesis.
Replicated reagent rehearsals simultaneously validate the
reproducibility of the synthetic procedures and the accept-
ability of reagents, while increasing the likelihood that any
individual member of a virtual, combinatorial D
3 catalog can
be made and remade. Although reagent rehearsal is currently
being done in combinatorial chemistry work,
22 it can be taken
to a new level of certainty through distributed replication in
student hands in different locations throughout the world.
This distributed process has now taken place in the United
States, Poland, Russia, and Spain, and is documented in an
accompanying article.
4 It provides powerful validation of the
distributed approach.
When target molecules are identiﬁed from virtual D
3
catalogs, their syntheses will similarly be replicated. This
replication provides the precedent required to give conﬁdence
in the ability, should it be needed, to resynthesize these hits
and to use the same synthetic procedures and reagent sets to
produce analogs in follow-up work. Since multiple research-
ers were involved in replicated syntheses of a promising lead,
even the scale-up work can be distributed, for example by
multiplying the replication of a given molecule in subsequent
distributed laboratories. Because the D
3 process can quickly
and reproducibly resynthesize molecules, only those small
quantities required for initial in vitro biological screening
need be made. This is in contrast to the more expensive
approach used in industry, which often synthesizes and
puriﬁes larger amounts of molecules even before they show
any interesting biological activity.
Attaining Appropriate Analytical Quality. An early
issue in combinatorial chemistry was the questionable
analytical quality of the molecules prepared. Some collections
contained either intentional mixtures or single molecules of
varying purities and characterization. Through inappropriate
follow-up work, these samples sometimes led to “false
positives”
23 and wasted effort. As a result, many research
programs now require the puriﬁcation, to >90-95% purity,
of all molecules prior to any screening.
24
There is no disputing the value of isolating substantially
pure and well-characterized molecules for testing in follow-
up structure/activity work. However, a universal, single-
compound purity criteria may not always be necessary at
the initial screening level. For example, with some screens
it may be reasonable, even desirable, to test mixtures
(enantiomers, diastereomers, or even more complicated
mixtures
25) from a single synthesis because there are
sophisticated and effective tools (mainly pioneered by natural
products chemists
26) to identify the active component(s) of
a mixture.
27 Bioassay-guided fractionation is especially
effective in this regard.
28 When needed, it can be performed
either at an underutilized centralized site, or as part of an
educational program in analytical laboratories that teach
students these skills. The important point at this stage is to
have a careful coordination of analytical and screening
expertise for quick and positive identiﬁcation of the active
component of a screen hit, regardless of the initial purity or
complexity of the tested sample. It is through this coordinated
effort that purity criteria should be established and hits
identiﬁed. In D
3, all products made will be analyzed for
purity, usually by a combination of liquid chromatography
and mass spectral identiﬁcation techniques.
29 When further
puriﬁcation is required prior to testing, this will be carried
out either in an academic laboratory (for example by students
as part of the educational process
5) or in a more centralized
facility.
Managing Expense. It is inherent in the combinatorial
problem solving process that the likelihood of ﬁnding a
solution is increased by performing multiple experiments.
This inevitably means making more molecules than required
for traditional problem solving. If D
3 is to be successfully
carried out using combinatorial chemistry, the ﬁnancial issues
accompanying this increased experimentation must be
addressed.
Critical cost categories in organic syntheses are personnel,
equipment, laboratory space, reagents, and waste disposal.
However, where the distributed computational screen saver
analogy applies, the implementation of D
3 synthesis requires
little or no additional expense. For example, undergraduate
students often seek the opportunity to participate in inde-
pendent research, facilitating the development of these
distributed laboratories. When these laboratories are imple-
mented in the educational process (at IUPUI as part of the
second semester undergraduate organic laboratory), the costs
of equipment, reagents, waste disposal, and teaching person-
nel are partially or completely covered by tuition and other
funding sources. As described in Part III, by having each
student perform six syntheses on a small scale (typically 50
µmol), and minimizing the need for intermediate puriﬁcation
steps, the cost can be kept close to the expense of a laboratory
in which each student conducts only one synthetic sequence
but on a scale 10-100 times larger (see Part III for a more
complete discussion of equipment and reagent needs).
Financial support for development of D
3 currently comes
from a variety of sources. The National Institutes of Health
(NIH) has funded the ongoing basic solution- and solid-phase
research subsequently adapted to D
3 chemistry. As mentioned
above, a large part of the student laboratory expense is
covered by tuition and private/public-supported funds. In our
laboratories, undergraduate research was funded by IUPUI
student tuition, scholarships, and grants, and by The Camille
and Henry Dreyfus Foundation. A private fund for Distrib-
uted Drug Discovery
30 ﬁnances the purchase of equipment
and supplies when educational money is limited. Eli Lilly
and Company has actively supported the Distributed Drug
Discovery effort. Future funding could come from non- and
Perspectives Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 7for-proﬁt organizations that have already demonstrated
interest in supporting the discovery of new drugs for
developing world diseases, and in increasing the level and
accessibility of science education in both the developed and
developing world.
2,7,11e
Part III. Implementation of D
3 Chemistry in the
United States, Poland, Russia, and Spain
Development of D
3 Combinatorial Chemistry Proce-
dures that Enable the Synthesis of any Member of
Large Virtual D
3 Catalogs of Potential Drug Leads. Over
the past twelve years a major objective in our research
program has been the development of solid-phase synthetic
methodology to varied classes of potentially biologically
active molecules.
31 It was natural to consider some of this
chemistry for the D
3 project. We focused ﬁrst on the
methodology we developed to synthesize a wide range of
resin-bound unnatural amino acids 1.
31a,c This generic
structure (including resin-bound naturally occurring amino
acids) is one of the most common types of intermediates
used in combinatorial chemistry. It is often embedded in
subsequent molecular scaffolds.
32,33 Scheme 1 gives just a
few of the many documented examples of libraries based
on 1.
31o,q,34-39
Our route to resin-bound analogs of 1
31 and their acylated
derivatives 5 (Scheme 2) offered an opportunity to document
the ability of students to make and use 1 in multiple D
3
projects.
In July of 2003, with strong support and encouragement
from the organizers of an NSF Workshop at Miami Univer-
sity,
40 early adaptations of this chemistry and equipment were
tested by a set of educators from small and large institutions.
With the success of this workshop, and further encourage-
ment and input from the participating educators (one of
whom helped coin the term “D
3”), we decided to make a
concerted effort to enable the D
3 concept. We enlisted the
help of undergraduate, graduate level and postdoctoral
researchers at IUPUI, in collaborative and independent
research, to adapt our published procedures to the scale,
equipment, and simplicity that would be required for D
3
incorporation into a standard second semester undergraduate
organic chemistry laboratory. It was assumed that students
in such a laboratory would have no prior exposure to
combinatorial chemistry or solid-phase organic synthesis. A
number of practical issues were considered, among them
reproducibility, time constraints, and solvent/reagent ex-
penses. From this developmental work, a formal laboratory
was designed and implemented at IUPUI in Fall 2004.
Variations of this laboratory have now been carried out over
twelve semesters at IUPUI, as well as at locations in Poland,
Russia, and Spain. This work is described in more detail
below, and in the following article in this Journal.
4
Design and Manufacture of Simple, Inexpensive Equip-
ment to Carry Out These Syntheses. Carrying out D
3
chemistry requires simple and low-cost equipment. While
there are numerous devices for conducting solid-phase
reactions, most do not meet the D
3 constraint of simplicity,
low cost, reusability, and especially, appropriate student
scale. We initially explored, at the Miami University NSF
Workshop, the use of equipment capable of conducting 24
combinatorial reactions at a time. However, it was clear that
it would be an overwhelming challenge to use in most
undergraduate laboratories. To proceed further, the equip-
ment, which was originally developed in industry,
41 was
redesigned to carry out six solid-phase reactions at a time,
o na2 5t o2 0 0µmol scale, in a 2 × 3 combinatorial grid.
The 3.5 mL reaction vessels, with screw caps on both ends
and a fused frit at one end, are made out of glass. This
provides inertness, durability, and long-term vessel reus-
ability, making these reaction vessels cost competitive with
disposable plastic cartridges. A picture of the kit, known as
Scheme 1. Role of Resin-Bound Amino Acids 1 as a Key
Combinatorial Intermediate
Scheme 2. Preparation of an Acylated Unnatural Amino Acid (5) Library
4,5
8 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Perspectivesa “Bill-Board 6-pack”, is shown in Figure 4. The Bill-Board
6-pack kit is manufactured locally at modest cost.
42
It should be emphasized that inherent in the D
3 concept
is an open-access approach to meeting all needs. This project
will fail if expensive synthesis equipment is required. In the
spirit of open access D
3, any alternative low-cost equipment
that would be more readily manufactured locally or enable
an alternative D
3 chemistry (solution or solid-phase based)
will be welcomed, used, and shared.
Successful Demonstration of Globally Replicated D
3
Synthesis. With the required chemical procedures and
equipment in place, it remained to be shown that the
distributed combinatorial synthesis that D
3 requires is practi-
cally feasible in everyday working educational laboratories
throughout the world. This goal has been accomplished.
Participating laboratories engage in either of two activities:
“reagent rehearsal” or “targeted library synthesis.” In the
rehearsal laboratories, diversity reagents are evaluated in a
replicated fashion for potential use at each step of a D
3
combinatorial synthesis and subsequent use in the enumera-
tion of virtual libraries. The targeted library synthesis
laboratories then synthesize a subset of the virtual D
3
catalogs.
For our ﬁrst exempliﬁcation of the “reagent rehearsal
laboratory”, we chose to evaluate alkylating agents R1X and
acylating agents R2COCl (or R2CO2H), in the synthesis of
acylated unnatural amino acid libraries (5, Scheme 2). This
enables the creation of a global database of reagents for
enumeration of a large, rehearsed (or otherwise precedented)
virtual catalog of acylated unnatural amino acids 5 or other
combinatorial libraries based on intermediate 1 (Scheme 1).
This laboratory was piloted at IUPUI in fall 2004. Second
semester beginning organic chemistry laboratory students
conducted a rehearsal of alkylating agents R1X. The twenty
participating students successfully carried out a total of 120
separate solid-phase reaction sequences. This laboratory was
expanded in spring 2005 to four sections with a total of sixty-
ﬁve students conducting 198 separate reactions. Later that
spring, the laboratory was conducted at the University of
Barcelona (Spain), and ﬁnally, in the summer of 2005, at
Moscow State University (Russia) and the Lublin School of
Pharmacy (Poland). With few exceptions, all rehearsal
syntheses were replicated satisfactorily, locally, and globally,
and a control molecule synthesized at multiple sites was
obtained with consistent purity. Currently over 40 alkylating
agents and 60 acylating agents have been evaluated. Part of
this work is reported in the following article, “Distributed
Drug Discovery, Part 2: Global Rehearsal of Alkylating
Agents for the Synthesis of Resin-Bound Unnatural Amino
Acids and Virtual D
3 Catalog Construction.”
4 New molecules
produced in this project have been submitted for biological
evaluation to the Small Molecules Library Repository created
as part of the NIH Molecular Libraries initiative.
10
The challenge of a “targeted library synthesis” laboratory
has also been met. It is crucial to the Distributed Drug
Discovery concept that we show that students can be
educated, at the same time they make, in a distributed
fashion, new molecules that have been rationally chosen
(targeted), from virtual D
3 catalogs. While waiting for
neglected disease drug-lead candidates to emerge from the
computational analysis of virtual D
3 catalogs, we wanted to
immediately demonstrate the ability of students to make
targeted, high quality, potentially biologically active mol-
ecules in the course of their normal educational laboratory
training.
In this regard, a biological target and class of molecules
(albeit for cancer and not uniquely a developing world
disease) was chosen, from our virtual catalog, for proof of
concept. An article from the Hergenrother group reported
that the (R)-phenylalanine derivative 7 induced apoptosis in
a melanoma (skin cancer) cell line (Figure 5).
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Students had already rehearsed alkylating agents that
produced racemic acylated phenylalanine analogs (Scheme
2, 5a,R 1 ) CH2Ar).
4 Thus, it was readily apparent that a
simple modiﬁcation of our current synthetic route could
provide for the rapid production, in a distributed fashion, of
the most active antimelanoma compound (7), along with new
analogs 8. As in the preparation for our ﬁrst rehearsal
laboratories, we enlisted the help of undergraduates, graduate
students, and postdoctoral researchers at IUPUI, in collabora-
tive and independent research, to adapt our published
procedures to the scale, equipment, and simplicity that would
be required for incorporation of a “targeted library synthesis”
laboratory into a routine undergraduate organic chemistry
laboratory. This was accomplished, and the laboratory
entitled “Solid-Phase Combinatorial Synthesis of Analogs
of an Anti-Melanoma Compound” was implemented at
IUPUI. The 20 undergraduate organic laboratory students
synthesized, in duplicate, 38 new analogs. These were then
puriﬁed by a single undergraduate research student. The
article describing this endeavor, entitled “Distributed Drug
Discovery, Part 3: Using D
3 Methodology to Synthesize
Analogs of an Anti-Melanoma Compound,” is the second
article following this Perspective.
5
D
3 Enumeration and Virtual Catalogs. A key compo-
nent of Distributed Drug Discovery is the open access
availability of synthetically precedented virtual D
3 catalogs
for global computational modeling. This modeling process
can identify subsets of molecules, capable of ready D
3
synthesis, as potential developing world drug-leads. With
documented D
3 synthetic procedures now in place, we have
Figure 4. Bill-Board equipment for Distributed Drug Discovery.
Figure 5. Generic structure 6, anti-melanoma lead 7, and analogs
8 accessible through D
3.
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freely available to the worldwide community. The two
catalogs are based on generic structures 5 and 6 (Figure 6).
The ﬁrst, a 24 416 compound catalog based on acylated
unnatural amino acids 5, is precedented by the work reported
in “Distributed Drug Discovery, Part 2: Global Rehearsal
of Alkylating Agents for the Synthesis of Resin-Bound
Unnatural Amino Acids and Virtual D
3 Catalog Construc-
tion.” This article immediately follows the Perspective.
4 The
second, a 24 192 member catalog based on acylated unnatural
amino acid methyl esters 6, is precedented by the work
reported in the subsequent article, “Distributed Drug Dis-
covery, Part 3: Using D
3 Methodology to Synthesize Analogs
of an Anti-Melanoma Compound.”
5 For enumeration of each
catalog, 100 alkylating agents or Michael acceptors were used
in the alkylation step (Scheme 2, 2-3), and 100 carboxylic
acids (Scheme 2, 1-4 using carboxylic acids instead of acid
chlorides) were used in the acylation step. The 24 416
theoretical acylated amino acids 5 would arise from cleavage
of the resin-bound products 4 with TFA, while the 24 192
acylated amino acid methyl esters 6 would come from
transesteriﬁcation cleavage with methanol. These combined
results afford a virtual D
3 catalog of 48 608 molecules. Since
the stereochemistry is not controlled in the alkylation step,
both stereoisomers are obtained at the R-carbon. Additional
stereoisomers, obtained when racemic or prochiral reactants
are used, are each represented uniquely in the virtual D
3
catalog. This stereochemical richness accounts for the greater
number of compounds in the catalogs than would result from
a simple 100 × 100 enumeration in each case.
All the reagents used in the enumeration of these catalogs
are commercially available and their compatibility with the
D
3 synthetic procedures is either documented in our two
subsequent articles or well-precedented in the literature. The
enumerations were conducted using commercial software,
18b
and the complete virtual D
3 catalog is freely available online
through the Collaborative Drug Discovery (CDD) interface.
12,44
Future Directions and Needs
We have identiﬁed six major goals to further the develop-
ment of D
3:
(1) Cataloging, with global open-access, biochemical
targets for developing world diseases, along with the
identiﬁcation of the molecule scaffolds (and function-
alization) appropriate for binding to these targets.
(2) Continued adaptation of solid- and solution-phase
combinatorial methodologies, from the basic research
level to D
3 compatible equipment and procedures, to
enable the simple, inexpensive distributed synthesis
of large numbers of these structurally diverse potential
drug-lead molecules.
(3) Establishment of a network to facilitate the creation
of additional virtual D
3 catalogs based on this D
3
chemistry, and to provide coordinated information
sharing and analysis, with global links, to computa-
tional chemists, distributed synthetic chemists and
biochemical screening resources.
(4) Development and/or identiﬁcation of computational
models relevant to developing world and other ne-
glected disease targets, and their utilization in the
analysis of virtual D
3 catalogs.
(5) Development and implementation of D
3 compatible
biochemical screens appropriate for these disease
targets.
(6) Identiﬁcation and establishment of the puriﬁcation,
registration, storage and sample submission resources
required to expedite the testing and tracking of
compounds made at global sites.
Summary
This Perspective describes, both conceptually and in
practical embodiment, a project developed at IUPUI that we
call Distributed Drug Discovery (D
3). This cross-disciplinary
program is grounded in the conviction that the major
challenge of developing drug leads for neglected diseases
can be addressed, at low cost and signiﬁcant educational
beneﬁt, through a distributed combinatorial discovery pro-
cess. This will be accomplished by dividing the computa-
tional, synthesis, and screening stages of drug discovery into
smaller units and developing simple procedures and inex-
pensive equipment to permit students, worldwide, to be the
problem solvers during their normal educational studies. This
connects them, in their training, to an ultimate application
of the skills and expertise they are learning. At the same
time it enables the problem of drug-lead discovery to be
economically addressed. Once drug leads are identiﬁed, other
nonproﬁt initiatives can shepherd them through the numerous
steps remaining to convert these leads into approved drugs,
and make them available, at low cost, to those in need.
Distributed computation is now well documented in drug
discovery. This Perspective focused on how combinatorial
chemistry can be utilized to enable the virtual catalog and
synthesis components of D
3. When distributed screening
methodologies are developed, the overall integrated process
will be in place. The chemistry component of D
3 envisions
two students (perhaps one in an undergraduate organic
laboratory in a developing world country and the other in a
laboratory in the developed world) synthesizing, in duplicate,
the lead molecule that is subsequently turned into a drug to
treat malaria, AIDS, tuberculosis, leischmaniasis, trypano-
somiasis, or some other disease widely affecting the develop-
ing world. It is our hope that D
3 will be a unifying concept
encouraging our colleagues throughout the world to join us
in developing and harnessing distributed global resources for
education, human development, and the discovery of drug
leads for developing world and other neglected diseases.
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